Literature DB >> 31210308

LncRNA TUG1 aggravates the progression of prostate cancer and predicts the poor prognosis.

T Xu1, C-L Liu, T Li, Y-H Zhang, Y-H Zhao.   

Abstract

OBJECTIVE: To explore the correlation between plasma level of lncRNA TUG1 with PSA level, Gleason grading and tumor node metastasis (TNM) stage of prostate cancer (PCa) patients. This study aims to evaluate the potential diagnostic and prognostic values of TUG1 in PCa. PATIENTS AND METHODS: Plasma level of TUG1 in 70 PCa patients and 70 healthy controls was determined using the quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). Correlation between plasma level of TUG1 with PSA level, Gleason grading and TNM stage of PCa patients was analyzed. The potential diagnostic value of TUG1 in PCa was explored by introducing the receiver operating characteristic (ROC) curve. The survival analysis of PCa patients undergoing radical prostatectomy was conducted using the Kaplan-Meier method and the log-rank test. Finally, the regulatory effects of TUG1 on in vitro proliferative and migratory abilities of PCa cells were examined by the cell counting kit-8 (CCK-8) and the transwell assay, respectively.
RESULTS: QRT-PCR data revealed a higher plasma level of TUG1 in PCa patients than in those of healthy controls. In particular, PCa patients with stage III+IV had a higher level of TUG1 relative to those with stage I+II. Moreover, the TUG1 level was higher in PCa patients with a higher PSA level (≥ 10 ng/mL), Gleason grading (≥ 7) or TNM stage (N1, M1). There was no significant correlation between the plasma level of TUG1 and the age of PCa patients. The ROC and Kaplan-Meier curves indicated the diagnostic and prognostic values of TUG1 in PCa. The overexpression of TUG1 markedly accelerated PCa cells to proliferate and migrate.
CONCLUSIONS: The plasma level of TUG1 is upregulated in PCa patients and is correlated to PSA level, Gleason grading and TNM stage of PCa. TUG1 exerts certain diagnostic and prognostic values in PCa. The overexpression of TUG1 markedly accelerates PCa cells to proliferate and migrate.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31210308     DOI: 10.26355/eurrev_201906_18062

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.784


  13 in total

Review 1.  Role of taurine, its haloamines and its lncRNA TUG1 in both inflammation and cancer progression. On the road to therapeutics? (Review).

Authors:  Stella Baliou; Anthony M Kyriakopoulos; Demetrios A Spandidos; Vassilios Zoumpourlis
Journal:  Int J Oncol       Date:  2020-07-14       Impact factor: 5.650

2.  Inhibition of long non-coding RNA TUG1 protects against diabetic cardiomyopathy induced diastolic dysfunction by regulating miR-499-5p.

Authors:  Lei Zhao; Weiguo Li; Hao Zhao
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

3.  Long non-coding RNA TUG1/microRNA-187-3p/TESC axis modulates progression of pituitary adenoma via regulating the NF-κB signaling pathway.

Authors:  Rui Zhang; Fan Yang; Haitao Fan; Haocong Wang; Qinghao Wang; Jianxin Yang; Tao Song
Journal:  Cell Death Dis       Date:  2021-05-21       Impact factor: 8.469

4.  Identifying Long Non-coding RNA of Prostate Cancer Associated With Radioresponse by Comprehensive Bioinformatics Analysis.

Authors:  Meng Xu; Shiqi Gong; Yue Li; Jun Zhou; Junhua Du; Cheng Yang; Mingwei Yang; Fan Zhang; Chaozhao Liang; Zhuting Tong
Journal:  Front Oncol       Date:  2020-04-07       Impact factor: 6.244

5.  Knockdown of lncRNA TUG1 Enhances Radiosensitivity of Prostate Cancer via the TUG1/miR-139-5p/SMC1A Axis.

Authors:  Dianhui Xiu; Lin Liu; Min Cheng; Xiaosong Sun; Xibo Ma
Journal:  Onco Targets Ther       Date:  2020-03-17       Impact factor: 4.147

6.  lncTUG1/miR-144-3p affect the radiosensitivity of esophageal squamous cell carcinoma by competitively regulating c-MET.

Authors:  Pan Wang; Zhuanbo Yang; Ting Ye; Fei Shao; Jiagen Li; Nan Sun; Jie He
Journal:  J Exp Clin Cancer Res       Date:  2020-01-09

7.  Long non-coding RNA TUG1 promotes cell progression in hepatocellular carcinoma via regulating miR-216b-5p/DLX2 axis.

Authors:  Qun Dai; Jingyi Deng; Jinrong Zhou; Zhuhong Wang; Xiao-Feng Yuan; Shunwen Pan; Hong-Bin Zhang
Journal:  Cancer Cell Int       Date:  2020-01-07       Impact factor: 5.722

8.  LncRNA Taurine Upregulated Gene 1 as a Potential Biomarker in the Clinicopathology and Prognosis of Multiple Malignant Tumors: A Meta-Analysis.

Authors:  Qi Huang; Jingjing Wu; Hui Wang; Na Li; Zhen Yang; Mingjun Zhang
Journal:  Dis Markers       Date:  2021-03-02       Impact factor: 3.434

9.  Comprehensive Pan-Cancer Analysis of the Prognostic and Immunological Roles of the METTL3/lncRNA-SNHG1/miRNA-140-3p/UBE2C Axis.

Authors:  Xiulin Jiang; Yixiao Yuan; Lin Tang; Juan Wang; Qianqian Liu; Xiaolan Zou; Lincan Duan
Journal:  Front Cell Dev Biol       Date:  2021-11-10

10.  The lncRNA NEAT1/miRNA-766-5p/E2F3 Regulatory Axis Promotes Prostate Cancer Progression.

Authors:  Wenhui Zhao; Xinshu Zhu; Qiu Jin; Bo Lin; Runyuan Ji
Journal:  J Oncol       Date:  2022-02-21       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.